IHL - INCANNEX NEWS ARTICLES, page-191

One of the key outcomes from the RespireRX 2b trials was

"based on these results..., we have concluded that expansion of dronabinol’s use into OSA and other therapeutic indications will require new, improved formulations."

So, by their own admission, dronabinol on Its own is not a suitable / effective treatment. This was realised back in 2017 so I expect our BOD were all over it and perhaps this finding helped to shape our drug development in terms of complimentary / synergistic combinations.

We'll find out more when they release the full set of results. Hopefully not too far away